Table 2.
| Subgroup Criteria | Placebo (n = 121) | Duloxetine (n = 249) |
| Aged ≥75 y | 42 (34.7) | 85 (34.1) |
| HDRS-17 total score > 19c | 51 (53.7) | 101 (49.5) |
| Pain (BPI mean pain score ≥ 3)d | 69 (59.0) | 141 (58.5) |
| Psychomotor retardation (HDRS-17 item 8 score ≥ 2)c | 28 (29.5) | 47 (23.0) |
| Orthostatic hypotensione | 30 (25.0) | 65 (26.2) |
| Neurologic condition | 31 (25.6) | 76 (30.5) |
| Gait condition | 67 (55.4) | 121 (48.6) |
| Cardiorespiratory condition | 44 (36.4) | 74 (29.7) |
| Alcohol consumption | 36 (30.0) | 80 (32.1) |
| Concomitant medication | ||
| Analgesics | 19 (15.7) | 30 (12.0) |
| Antihypertensives | 69 (57.0) | 143 (57.4) |
| Benzodiazepine/nonbenzodiazepine sleep agents | 43 (35.5) | 79 (31.7) |
| Other sedating medications | 28 (23.1) | 58 (23.3) |
a
Data are presented as n (%).
b
Percentages were calculated based on the number of patients with nonmissing data.
c
Placebo: n = 95; duloxetine: n = 204.
d
Placebo: n = 117; duloxetine: n = 241.
e
Placebo: n = 120; duloxetine: n = 248.
Abbreviations: BPI = Brief Pain Inventory, HDRS-17= 17-item Hamilton Depression Rating Scale.